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Hepatitis B virus (HBV) viral load (VL) is used as a biomarker to assess 
risk of disease progression, and to determine eligibility for treatment. 
While there is a well recognised association between VL and the 
expression of the viral e-antigen protein, the distributions of VL at a 
population level are not well described. We here present cross-
sectional, observational HBV VL data from two large population 
cohorts in the UK and in South Africa, demonstrating a consistent 
bimodal distribution. The right skewed distribution and low median 
viral loads are different from the left-skew and higher viraemia in seen 
in HIV and hepatitis C virus (HCV) cohorts in the same settings. Using 
longitudinal data, we present evidence for a stable ‘set-point’ VL in 
peripheral blood during chronic HBV infection. These results are 
important to underpin improved understanding of HBV biology, to 
inform approaches to viral sequencing, and to plan public health 
interventions.
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            Amendments from Version 1
We have made it clear that we are not trying to directly compare 
HBV/HCV and HIV, more give a broad overview of how the viruses 
differ and how this may be due to underlying virus/host interplay. 
We have restructured our discussion, adding a ‘limitations and 
caveats’ section to our manuscript acknowledging the cohorts 
compared from the UK and South Africa are very different 
and our main aim is to demonstrate that inspite of their 





Hepatitis B virus (HBV) DNA viral loads (VL) show wide 
variation between individuals with chronic hepatitis B (CHB) 
infection, and are used to determine treatment eligibility1. 
The relationship between HBV e-antigen (HBeAg)-positive 
status and high VL in CHB is well recognised, but there 
are few refined descriptions of VL distribution, and limited 
understanding of the biology that underpins these patterns. Set 
point viral load (SPVL), defined as a stable level of viraemia 
in peripheral blood during the initial years of chronic infec-
tion, is a concept well established in HIV2. However, despite 
many biological similarities between HIV and HBV viral 
replication cycles, SPVL has not been explored for CHB to date.
Developing improved insights into the distribution of VL at 
a population level is important for planning wider treatment 
deployment to support progress towards international sustain-
able development goals for HBV elimination, which set ambi-
tious targets for reducing morbidity and incidence of new CHB 
cases3. Characterisation of HBV VL dynamics is also impor-
tant for mathematical modelling, and for generating new 
insights into persistence, transmission and pathogenesis. To 
support development of in vitro research, understanding the 
VL distribution at a population level informs approaches to viral 
sequencing, which typically have thresholds of 103–104 iu/ml, 
below which sequences cannot be derived.
We have therefore set out to generate a preliminary 
description of the HBV VL distribution in independ-
ent cohorts from the UK and South Africa, to compare 
these patterns with VL distributions in two other chronic 
blood-borne viral infections, HIV-1 and hepatitis C virus (HCV), 
and to seek evidence for SPVL in HBV infection.
Methods
We retrospectively collected VL measurements ± supporting 
metadata for adults with chronic HBV, HCV and HIV 
infection from four cohorts: 
(i) HBV: UK dataset
 We collected data for adults (>18 years) with CHB infec-
tion (defined as positive HBsAg on ≥2 occasions ≥ 6 months 
apart) from electronic records at Oxford University Hospitals 
NHS Foundation Trust, as part of the National Institute 
of Health Research Health Informatics Collaborative 
(NIHR-HIC), as previously described4. We assimilated VL 
results (Abbott M2000 platform) for 371 individuals off 
nucleoside analogue therapy over six years commencing 
1st January 2011, for whom baseline HBeAg status was 
available in 351 (95%) cases. Age, sex and self-reported 
ethnicity (using standard ethnicity codes) were available 
for 352, 355 and 322 individuals, respectively. For longitu-
dinal VL analysis, we only used data prior to commencing 
antiviral treatment, including patients with ≥2 measurements 
≥6 months apart (n=299 individuals, 1483 timepoints). 
The upper limit of quantification is HBV DNA 108 IU/ml.
(ii) HBV: South Africa dataset
 We collected all HBV VL data from the South African 
National Health Laboratory Service (NHLS) recorded over 
a four year period commencing 1st January 2015 (n=6506 
individuals). These were generated using various commer-
cial platforms in different NHLS labs across the country. 
Other metadata (HBeAg status, HIV status, treatment 
data) were not available. For the purposes of analysis, we 
excluded VL measurements below the limit of detection 
based on the assumption that the majority of these samples 
were taken on antiviral treatment (indicated for HBV 
infection ± HIV co-infection). All those above the labora-
tory limit of quantification were designated 1.7×108 IU/ml. 
For analysis of longitudinal data, we included patients 
with ≥2 detectable VL measurements (n=874 individuals; 
9578 timepoints).
(iii) HCV
 Baseline HCV viral loads were collected for adults prior 
to commencing antiviral treatment between 2006–2018, 
representing 925 individuals, from the same source as 
the UK HBV data using the Abbott M2000 platform, and 
collected through the NIHR-HIC pipeline. The setting and 
characteristics of this study population has been previously 
described5. 
(iv) HIV
 HIV data were obtained from a UK database of HIV sero-
converters between 1985-2014 through the BEEHIVE 
collaboration (n=1581)2. HIV VL was measured using 
COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 on 
samples collected starting at 6-24 months after infection. 
SPVL was defined as the average VL for each patient over 
time, as previously described2.
Statistical analysis
We used Graphpad Prism v.8.2.1 for analysis of VL distributions, 
skewness, and univariate analysis of patient parameters 
associated with HBV VL (Mann Whitney U test and 
Kruskall Wallis test). HBV and HCV VL are conventionally 
reported in IU/ml, but to make direct comparisons between 
VL in different infections, we also converted data into copies/ml 
(1 IU = 5.4 copies/ml for HBV6 and 2.7 copies/ml for 
HCV7.
We used R package (version 3.6.1) to assess within and 
between patient VL variability, using longitudinal data from UK 
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HBeAg-negative adults, and from South African individuals 
with detectable VL. A large contribution of between-host 
variation would provide support for SPVL. We defined total 
variation, between-individual and within-individual variation 
according to analysis of variance (ANOVA). Specifically, the 




























n denotes the number of individuals; n
i
 represents the number 
of data points for individual i; x
it
 denotes the viral load of 
patient i at time point t; x  is the mean of viral loads of all data 
points; ix  is the mean of viral loads of patient i.
Ethics
Data collection for the UK cohort was approved as part of 
the NHS Health Informatics Collaborative (NHIC Hepatitis 
Theme Database) by the NRES Committee South Central-
Oxford C (ref: 15/SC/0523), allowing routine clinical data 
to be collated and analysed in anonymised form as described 
previously4,8. South African data collection was approved by the 
Health Sciences Research Ethics Committee at the University 
of the Free State (ref: UFS-HSD2019/0044/2603). In both cases, 
approval was given without the need for individual patient 
consent, as data were collected in anonymised form without 
identifying details.
Results
Our UK HBV cohort was 56% male, median age 42 years, 
with diverse ethnic backgrounds (among 322 individuals 
with self-reported ethnicity data, 38% were Asian, 34% 
White, 24% Black, 4% Arabic, <1% other). Overall, median 
HBV VL was 3.4 log
10
 IU/mL; 95% CI 3.2 – 3.5 log
10
 IU/mL 
(equivalent to median 4.2 log
10
 copies/ml). There was a bimodal VL 
distribution with two peaks: 
 (i) HBeAg-negative infection (accounting for 304/351 
(87%) of measurements): median VL 3.2 log10 IU/mL 
(95% CI 3.0 – 3.4); right-skewed distribution (Figure 1A;9);
(ii) HBeAg-positive infection (accounting for 47/351 
(13%) of measurements): median VL 7.6 log
10
 IU/mL 
(95% CI 5.6 – 8.2); left-skewed distribution (Figure 1B;9).
In the South African dataset (HBeAg status not determined), 
median HBV VL was 4.6 log
10
 IU/mL (95% CI 3.9 – 4.0), with 
a bimodal distribution and right-skew (Figure 1C;9). Median 
HIV VL was 4.5 log
10





copies/ml), with a left skew and no 
bimodal distribution (Figure 1D,E;9).
For the UK data we investigated whether sex, age or ethnicity had 
any influence on VL; the only significant association was lower 
VL with increasing age in the HBeAg-positive group (p=0.01 
by Kruskal Wallis, Supplementary Figure 1; extended data9).
Inter-patient variation accounted for 82.7% and 88.0% of the 
variability in UK and South African longitudinal datasets respec-
tively, whilst within-patient variation accounted for 17.3% 




In this short report, we describe a consistent bimodal distribution 
of VL in CHB in a diverse UK population and a large South 
African dataset, in keeping with previously published studies 
(e.g. 10), and reflecting the role of HBeAg in immunomodulation11. 
However, descriptions of this pattern have not previously 
been carefully refined. This is the first study to demonstrate the 
concept of SPVL in HBV infection, with between-host 
factors explaining >80% of the variation in VL during 
HBeAg-negative CHB.
Inferences based on the distribution of viral loads
HBV viral loads in HBeAg-negative infection are significantly 
lower than HCV and HIV, which may relate to differences in 
viral population structure, viral fitness, host immune responses, 
and the availability of target cells. These factors might also 
explain why HIV, HCV and HBeAg-positive infection have 
left skew VL distributions, whereas HBeAg-negative infection 
has a right skew. Broadly, the biological significance of the 
relationship between VL and HBeAg status could be considered 
in two ways, first by addressing the mechanisms that underpin 
viraemic control, and second by considering the impact of 
alterations in VL on disease outcomes, including inflammatory 
liver disease, cancer and cirrhosis. These could not be addressed 
within this current dataset, but remain important questions 
for future research.
Limitations and caveats
The cohorts on which we report are different in many ways 
(host and viral genetics, demographics, environmental fac-
tors, access to treatment and laboratory monitoring), and for this 
reason we do not set out to make any statistical comparisons 
between cohorts in different settings. Rather, we make the 
more general observation that in spite of these many potential 
differences, the overall bimodal distribution of HBV viral loads 
is broadly consistent. A smaller proportion of individuals with 
high viraemia in the UK cohort is likely to be reflective of wider 
access to suppressive antiviral therapy. Missing metadata is a 
limitation for further analysis of our South African dataset, 
and longer term aspirations will be to investigate larger VL 
datasets together with more robust longitudinal clinical and 
laboratory data.
Implications for HBV sequencing
Whole genome sequencing has the potential to increase our 
understanding of HBV, but approximately 50% of cases fall 
below the current sequencing threshold12. This means that at 
present there is a significant ‘blind spot’ in sequence data, 
preventing analysis of sequence variants in individuals with 
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Figure 1. Distribution of viral loads (VL) for adults with chronic infection with Hepatitis B virus (HBV), Human Immunodeficiency 
Virus  (HIV) and Hepatitis C virus  (HCV). Panels A-C show VL distribution in HBV infection; D shows VL distribution in HIV infection; 
E shows VL distribution in HCV infection. Number of individuals represented, median viral load, and skewness of distribution are reported on 
individual panels A–E. IU/ml is standard approach to quantification for HBV and HCV (panels A, B, C, E), versus copies/ml routinely reported 
for HIV (panel D).
VL below the population median. The data presented in this 
report highlight the current challenges for HBV sequencing, 
and a need for resource investment to improve the sensitivity of 
sequencing approaches, for example considering amplification or 
enrichment approaches.
Conclusions and future aspirations 
Enhanced descriptions of HBV VL may shed light on the 
biology of chronic HBV infection, inform mathematical models 
of viral population dynamics within and between hosts, improve 
understanding of risk factors for transmission and disease 
progression, underpin optimisation of viral sequencing methods, 
and help to stratify patients for clinical trials and treatment.
Data availability
Underlying data
Figshare: Supporting data for an analysis of HBV viral load 
distribution and set point in chronic infection: retrospective 
analysis of cohorts from the UK and South Africa. https://doi.org/ 
10.6084/m9.figshare.11365082.v29
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-    191217 HBV VL data South Africa.xlsx (Including baseline 
VL data for each patient in the South African patient 
cohort and longitudinal values where measured)
-    200115 HBV VL metadata file.xlsx (Including baseline 
VL data for each patient in the UK patient cohort and 
longitudinal values where measured)
Extended data
Figshare: Supporting data for an analysis of HBV viral load 
distribution and set point in chronic infection: retrospective 
analysis of cohorts from the UK and South Africa. https://doi.org/ 
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-    200115 Suppl Fig 1.pdf
Supplementary Figure 1: Relationship between hepatitis B 
viral load, HBeAg status and (A) sex, (B) age, and (C) ethnic-
ity, in a cohort of adults with chronic hepatitis B virus infection 
recruited in Oxford, UK.
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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Gilles Wandeler  
Department of Infectious Diseases, Bern University Hospital, Bern, Switzerland 
This is an interesting study describing HBV VL distribution in two cohorts of HBV-infected 
individuals, with the aim to assess inter-person and intra-person variability. 
 
My main remarks are the following:
The most interesting and novel part of the paper is the analysis of variability of VL (last 
paragraph of the results). The authors could have gone a bit further in this analysis and its 
discussion. How did the inter-person and intra-person variability compare with HIV and 
HCV? What is the threshold of inter-personal variability needed to be able to conclude that 
there is a reliable set-point? How was this defined in HIV? I miss a discussion of the parallel 
that can be made between HIV infection (in which there is a large body research on VL set-
point) and HBV. This should be expanded given that it’s the main message of the paper. 
 
○
According to the authors, a key aim of the paper is to inform sequencing approaches. But in 
the current version of the paper I don’t know how the results shown are helpful to this end. 
It is known from many studies that a large proportion of HBeAg negatives have a low VL. 
However, it could be interesting to discuss how the low intra-person variability could be 
helpful in determining TX eligibility from one single measurement. This could be important 
for low-income countries. Could there be any risk factors for having a very unstable VL over 
time? This could help determine who needs repeat VL. 
 
○
I didn’t see a justification for including the RSA cohort, as HBeAg status and other 
demographic/clinical characteristics are not know in this cohort. If there’s a clear reason or 
advantage of including data from RSA (power size for variability analysis?), then the authors 
should underline this. Inter and intra-person variability are evaluated based on HBeAg-neg 
from UK and both HBeAg-pos and neg from RSA: this “dilution” of the HBeAg aspect may 
bias the results. This should be discussed in the limitations.
○
Minor comments:
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Results: Not clear from first para of text and figure if only one value per person was 
included or the full dataset for A and B. 
 
○
Results: Figure 1F is never mentioned in the text of the results section. 
 
○
Discussion: First para: last sentence should not be about HBeAg-neg as in RSA both HBeAg-
neg and pos. are included.
○
 
Is the work clearly and accurately presented and does it cite the current literature?
Partly
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: HIV and viral hepatitis.
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard.
Reviewer Report 02 November 2020
https://doi.org/10.21956/wellcomeopenres.17928.r40901
© 2020 Zhai X. This is an open access peer review report distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited.
Xiangjun Zhai  
Jiangsu Province Center for Disease Prevention and Control, Jiangsu, China 
I think the revisions are appropriate.
 
Is the work clearly and accurately presented and does it cite the current literature?
 
Page 8 of 13
Wellcome Open Research 2020, 5:113 Last updated: 19 APR 2021
Partly
Is the study design appropriate and is the work technically sound?
Partly
Are sufficient details of methods and analysis provided to allow replication by others?
Partly
If applicable, is the statistical analysis and its interpretation appropriate?
Partly
Are all the source data underlying the results available to ensure full reproducibility?
Partly
Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Prevention and control of infectious diseases such as Hepatitis B, HIV, TB
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard.
Version 1
Reviewer Report 07 September 2020
https://doi.org/10.21956/wellcomeopenres.17485.r40064
© 2020 Zhai X. This is an open access peer review report distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited.
Xiangjun Zhai  
Jiangsu Province Center for Disease Prevention and Control, Jiangsu, China 
As for the study design, the study selected 4 cohorts to study the VL distribution 
characteristics, but the basic characteristics of the 4 study cohorts are unclear or very 
different, the results are not comparable. For example, the metadata (HBeAg status, age, 
treatment data) were not available, but all of these characteristics are very important 
factors affecting the distribution of VL. 
 
1. 
The definition or biological significance of the set-point viral load in chronic HBV infection 
patients is unclear. For example, in the tolerant phase of HBV infection, the viral load can be 
maintained at a high level, while in the inactive phase of HBeAg negative, the viral load can 
2. 
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be maintained at a low level. Can the authors explain the biological significance of the set 
point viral load of the patients? 
 
As for the Figure 1F, I don't think VL of different viruses (HBV, HCV, HIV) can be compared 
among the infected patients.  
 
3. 
In the discussion, the authors stated that the between-host factors explain >80% of the 
variation in VL during HBeAg-negative CHB. But the VL variability within and between 
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As for the study design, the study selected 4 cohorts to study the VL distribution 
characteristics, but the basic characteristics of the 4 study cohorts are unclear or very 
different, the results are not comparable. For example, the metadata (HBeAg status, age, 
treatment data) were not available, but all of these characteristics are very important 
factors affecting the distribution of VL. 
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We agree with the reviewer about the differences between cohorts, and that we 
cannot determine host or viral factors that are associated with the viral load 
distributions we observe. We recognise that the text of our manuscript can be 
improved accordingly, and have made the following modifications:
We have removed the reference to ‘precise determinants’ of viral load from the 
abstract, and have taken out an aspiration to link VL to host characteristics 
from the methods, which were potentially misleading. Instead, we have 
simplified the abstract to say: 'While there is a well recognised association 
between VL and the expression of the viral e-antigen protein, the distributions 
of VL at a population level are not well described’. We have also improved clarity 
in the abstract by stating explicitly that the approach is an observational one.
1. 
A key learning point from these data is to inform HBV sequencing, which was 
not well represented in the introduction (although featured in the discussion); 
we have added this to make it clear that our intention is to provide an 
observation and description of HBV viraemia, rather than to make mechanistic 
insights or to draw direct comparisons between populations. We have amended 
the final sentence of the abstract to include the point about sequencing. 
2. 
We have structured the discussion with sub-headings to add clarity. Reflecting 
the point raised by the reviewer, we have added to ‘limitations and caveats’ 
section to say: ‘The cohorts on which we report are different in many ways (host 
and viral genetics, demographics, environmental factors, access to treatment 
and laboratory monitoring), and for this reason we do not set out to make any 
statistical comparisons between cohorts in different settings. Rather, we make 
the more general observation that in spite of these many potential differences, 
the overall bimodal distribution of HBV viral loads is consistent’. 
3. 
We recognise that a bigger metadata set would be of huge value, but providing 
this on a national level would not be feasible for any setting, and certainly not 
for South Africa where there are substantial clinical and laboratory resource 
constraints. However, our report is a very unusual opportunity in sharing viral 
load data for a whole country. We have added to the discussion: ‘The South 
African dataset represents viral load data for the whole country; assimilating 
wider clinical or laboratory metadata is not currently practical. In many 
low/middle income settings, biomarkers such as HBeAg status are infrequently 
measured due to resource constraints. Furthermore, linkage between clinical 
data (such as treatment) and laboratory data (such as viral load) is challenging 
at a national level for even high income settings.’ For this reason, we have 
formulated our observations into a short report, rather than a full length paper; 
we believe this is a proportionate way to share observational data which 
underpins questions for future research into the associations and determinants 
of viral load.
4. 
The definition or biological significance of the set-point viral load in chronic HBV infection 
patients is unclear. For example, in the tolerant phase of HBV infection, the viral load can be 
maintained at a high level, while in the inactive phase of HBeAg negative, the viral load can 
be maintained at a low level. Can the authors explain the biological significance of the set 
point viral load of the patients? 
 
We agree this is a really interesting question. This difference in set-point according to 
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eAg status is highlighted by Figure 1A vs 1B. The ‘biological significance’ of this 
observation could be considered in two ways, first addressing the mechanisms 
underlying the marked difference in viral loads, and second by considering the impact 
of this change on driving pathology. These are both complex questions, that remain to 
be clearly elucidated and are outside the remit of this current paper; rather than 
setting out to address these questions, the aim of this short report is to provide 
observational data that is a foundation for future research. We have added this point 
to the discussion. 
  
As for the Figure 1F, I don't think VL of different viruses (HBV, HCV, HIV) can be compared 
among the infected patients.  
 
We agree that a direct comparison between viral loads is difficult, but are intended to 
reflect a broad comparison between the host/viral interplay for different infections. 
 We have amended the abstract to remove the statement that the HBV, HCV and HIV 
cohorts are ‘comparable’ and instead say the cohorts are ‘in the same setting’. This 
removes any implication that direct comparison is appropriate. We have removed 
panel F and the sentence that compared median viraemia that supported this figure 
panel in the text of the results section. 
  
In the discussion, the authors stated that the between-host factors explain >80% of the 
variation in VL during HBeAg-negative CHB. But the VL variability within and between 
patient was not given in the parts of results. 
 
The results about within/between patient variability is already included in the results, 
as follows: ‘Inter-patient variation accounted for 82.7% and 88.0% of the variability in 
UK and South African longitudinal datasets respectively, whilst within-patient 
variation accounted for 17.3% and 12.0%. This provides support for a stable SPVL 
within individuals with CHB.’ We think this provides the information that the reviewer 
is seeking, but would welcome further specific feedback if additional amendment is 
thought to be required. 
 




Is the study design appropriate and is the work technically sound?○
Partly 
Having improved the aims and methods to state more clearly our intention to present 
an observational comment about distribution of viral loads, and removing the direct 
comparison between HIV, HCV and HBV, we believe we have addressed any concerns.




If applicable, is the statistical analysis and its interpretation appropriate?○
Partly 
As above, we think that changes to the methods and results (specific details set out 
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above, and removal of panel 1F) tackle any deficiencies in the first version.




Are the conclusions drawn adequately supported by the results?○
Partly 
An improved and expanded discussion section has allowed us to present conclusions 
more clearly, and we have improved on objective reporting of where primary 
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